

Supplementary Figure 4: RUNX2 expression after different treatments during 24h in MCF-7. RUNX2 was evidenced by immunofluorescence and was localized in the nucleus. Estrogens (E) and CDCA (CDCA) induced an increase of RUNX2 expression compared to the control (C). 4-hydroxytamoxifen (T), fulvestrant (F), LCA (L) and Z-guggulsterone (G) caused no variation of RUNX2 expression compared to the control (C). 4-hydroxytamoxifen and fulvestrant co-administered with estrogens or with CDCA (E+T, E+F, CDCA+T, CDCA+F) caused a decrease of RUNX2 expression versus estrogens (E) or CDCA (CDCA) used alone. LCA and Z-guggulsterone used in combination with estrogens (E+L, E+G) induced no variation of RUNX2 expression versus an exposure to estrogens (E) alone. LCA and Z-guggulsterone co-administered with CDCA (CDCA+L, CDCA+G) elicited a decrease of RUNX2 expression compared to CDCA (CDCA) used alone. Scale bars = 100 µm.